Physician profile

Mary E Ryan

Family · Kansas City, MO

NPI 1801857206

$1,999.96

in general payments reported to CMS, 2019-2025

25 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $399.60 2021
Biohaven Pharmaceuticals, INC. $312.14 2021
Lilly USA, LLC $234.96 2021
Novo Nordisk INC $156.96 2021
Amgen INC. $119.36 2021
Takeda Pharmaceuticals U.S.A., INC. $113.24 2021
Boehringer Ingelheim Pharmaceuticals, INC. $93.13 2021
Merck Sharp & Dohme LLC $81.61 2021
Pfizer INC. $70.34 2021
Currax Pharmaceuticals LLC $69.21 2021
Abbott Laboratories $60.85 2021
Astrazeneca Pharmaceuticals Lp $39.87 2021
Eisai INC. $33.90 2021
Amarin Pharma, INC. $31.10 2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $26.02 2021
Show all 25 companies
CompanyGeneral paymentsYearsTop products
Bausch Health US, LLC $25.67 2021
Kowa Pharmaceuticals America, INC. $24.48 2021
Esperion Therapeutics, INC. $16.03 2021
Ironshore Pharmaceuticals INC. $14.71 2021
Endo Pharmaceuticals INC. $14.64 2021
Daiichi Sankyo INC. $13.38 2021
Janssen Pharmaceuticals, INC $12.66 2021
Exeltis, USA INC. $12.19 2021
Glaxosmithkline, LLC. $12.11 2021
Novartis Pharmaceuticals Corporation $11.80 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mary E Ryan

$1,999.96

in general payments reported 2019-2025

Years
2021
Top company
Abbvie INC.

https://glasscript.com/doctor/10580705/mary-e-ryan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.